ࡱ >
\ p None B a = c @ = Z ?N*8 X" 1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial General ` Table_2 ;A 9 Screening Test Used Patient Tested' Actual Case Identification-n (%)
False+? Actual Performance Estimates-% (95% confidence interval) Acute HIV Established HIV All HIV Sensitivity Specificity
PPV
NPV Oraquick Advance (Oral Fluid RT) 6446
0/11 (0.0) 110/116 (94.8) 110/127 (86.6) 5 86.6 (79.4, 92.0) 99.9 (99.8, 100.0) 95.7 (90.1, 98.6) 99.7 (99.6, 99.8)' Oraquick Advance (Fingerstick blood RT) 8127
0/18 (0.0) 226/228 (99.1) 226/246 (91.9) 1 91.9 (87.7, 95.0) 100.0 (99.9, 100.0) 99.6 (97.6, 100.0) Vironostika HIV-1 Microelisa 2860
0/22 (0.0) 262/262 (100.0) 262/284 (92.3) 0 92.3 (88.5, 95.1) 100.0 (98.6,100.0) 99.2 (98.7, 99.5) Genetic Systems HIV 1/2 Plus O 3801
3/7 (27.3)
97/97 (100.0) 100/104 (96.2) 96.2 (90.4, 98.9) 100.0 (96.4, 100.0) 99.9 (99.7, 100.0) All Clinical Testing 21234
4/58 (6.9) 694/703 (98.7) 698/761 (91.7) 6 91.7 (89.5, 93.6) 99.1 (98.2, 99.7)
d MbP?_ %
* + &P &F